Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost–utility analysis of the tREACH trial | Zendy

AI Assistant Blog Pricing

Best cost-effectiveness and worker productivity with initial triple DMARD therapy compared with methotrexate monotherapy in early rheumatoid arthritis: cost–utility analysis of the tREACH trial

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.